The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons.
DDAVP (1-desamino-8-D-arginine vasopressin) was administered intranasally to 20 normal persons and blood was collected at various intervals up to 72 h. Plasma concentrations of VIII:C, VIIIR:Ag and fibrinolytic activity were increased by DDAVP with peak levels observed 1 h after the administration. Factors V, IX, XI, XII, XIII, P-APT time, platelets, platelet factor 3, P&P, AT III, alpha 2AP, fibrinogen and FDP were unchanged by the treatment. No side effects or changes in plasma Na or osmolality were observed. The present data demonstrate the selectivity of the effect of DDAVP on the coagulation system and points towards the possibility of using DDAVP in blood donors to increase plasma contents of factor VIII.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D001127:Arginine Vasopressin / Q000008:administration & dosage*; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000032:analysis; D001792:Blood Platelets / Q000187:drug effects; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005169:Factor VIII / Q000032:analysis; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D009994:Osmolar Concentration; D012964:Sodium / Q000097:blood; D013268:Stimulation, Chemical
D001779:Blood Coagulation Factors; D001127:Arginine Vasopressin; D005169:Factor VIII; D012964:Sodium; D003894:Deamino Arginine Vasopressin